Antidepressant Withdrawal Guides

Abilify (aripiprazole) has a relatively mild discontinuation profile compared to other atypicals, helped by its very long half-life. The clinically important concerns are the return of underlying psychiatric symptoms and, in rare cases, withdrawal dyskinesia (involuntary movements that emerge or worsen on discontinuation).

Stimulant discontinuation is more accurately called "rebound" or "crash" than withdrawal in the classical sense. Patients stopping Adderall after chronic use experience a constellation of symptoms driven by dopamine and norepinephrine depletion, but the syndrome is not life-threatening the way benzodiazepine or alcohol withdrawal can be. The rebound is real and uncomfortable, especially fatigue and the return of underlying ADHD symptoms, but it resolves within 1-3 weeks for most patients.

Ambien (zolpidem) is technically not a benzodiazepine but acts on the same GABA-A receptor complex, and chronic use produces similar dependence. Withdrawal is dominated by rebound insomnia, often pronounced enough that patients return to the medication immediately. Seizure risk on abrupt cessation after long-term high-dose use is real, though less than with traditional benzodiazepines.

Amitriptyline (Elavil) has a notable discontinuation pattern dominated by anticholinergic rebound. Abrupt cessation can produce a flu-like cholinergic rebound (sometimes called "TCA discontinuation syndrome") that is distinct from the SSRI pattern. Most patients can taper without major difficulty when the schedule is gradual.

Ativan (lorazepam) has a substantial withdrawal pattern similar to Xanax, though the longer half-life makes the inter-dose withdrawal less pronounced. As with all benzodiazepines, abrupt cessation after chronic use carries seizure risk and tapering should be done under medical supervision.

Auvelity is a newer FDA-approved antidepressant (2022) that combines an NMDA receptor antagonist (dextromethorphan) with an NDRI (bupropion). Discontinuation data is more limited than for older agents. Reported withdrawal patterns appear similar to bupropion alone given the bupropion component dominates the longer-term effects.

Buspar (buspirone) has a very mild discontinuation profile and does not produce a meaningful withdrawal syndrome. This is one of the reasons buspirone is preferred over benzodiazepines for chronic anxiety in patients without acute panic.

Celexa has a moderate discontinuation profile similar to its single-enantiomer cousin Lexapro. The relatively long half-life smooths the washout, and most patients can taper without significant difficulty when the schedule is gradual.

Clomipramine (Anafranil) has a moderate discontinuation profile that combines TCA cholinergic rebound with SSRI-pattern serotonergic withdrawal, because clomipramine is the most serotonergic of the TCAs. OCD return is the most clinically important phenomenon for patients tapering clomipramine.

Concerta (methylphenidate ER) has a smoother discontinuation pattern than Ritalin IR because the OROS formulation produces a more gradual serum-level curve. Rebound is generally milder. Otherwise similar pharmacology to Ritalin.

Cymbalta (duloxetine) has one of the most challenging discontinuation profiles among the SNRIs, second only to Effexor. The combination of a short half-life and dual serotonergic-noradrenergic activity produces vivid withdrawal symptoms. Compounded difficulty: Cymbalta is only available in 20, 30, and 60 mg capsules, with no liquid formulation, which makes fine titration difficult during the final phase of tapering.

Depakote does not produce a classical withdrawal syndrome. As with other mood stabilizers and anticonvulsants, the clinically important risks on discontinuation are mood relapse in bipolar patients and seizure recurrence in epilepsy patients. Slow tapering is the standard.

Desipramine (Norpramin) has a milder discontinuation profile than the more sedating TCAs like amitriptyline because it has lower anticholinergic activity. Most patients can taper without significant difficulty.

Doxepin discontinuation depends heavily on dose. Low-dose use (3-6 mg, Silenor for sleep) produces minimal withdrawal. Higher antidepressant doses (75-300 mg) produce a TCA-pattern withdrawal with cholinergic rebound similar to amitriptyline.

Effexor (venlafaxine) is widely recognized as having one of the most pronounced antidepressant discontinuation syndromes. The combination of a short half-life and dual serotonergic-noradrenergic activity means that even a single missed dose can produce symptoms; abrupt cessation reliably produces them. The XR (extended-release) formulation smooths peaks but does not change the underlying withdrawal physiology.

Emsam (transdermal selegiline) has a milder discontinuation pattern than oral MAOIs at low doses because of its MAO-B selectivity. At higher doses the pattern resembles other MAOIs. Most patients tapering Emsam describe sleep changes and return of depression as the dominant experiences.

Fetzima (levomilnacipran) has a discontinuation pattern similar to other short-half-life SNRIs. Less commonly prescribed than Cymbalta or Effexor, so patient communities discussing withdrawal are smaller, but the same physiology applies.

Geodon (ziprasidone) has a moderate discontinuation profile. The shorter half-life means rebound effects can emerge quickly. Less commonly prescribed than other atypicals but used for both schizophrenia and bipolar disorder.

Halcion (triazolam) has the shortest half-life of the commonly-prescribed benzodiazepines. This makes inter-dose withdrawal and rebound insomnia particularly pronounced. Chronic use is uncommon now, but for patients who do use it chronically, the withdrawal pattern can be intense given the rapid offset.

Imipramine has a discontinuation pattern dominated by cholinergic rebound, similar to amitriptyline. Less commonly prescribed now than in the past. Most patients can taper without major difficulty when the schedule is gradual.

Klonopin (clonazepam) has a more gradual withdrawal pattern than Xanax or Ativan because of its long half-life, but the underlying severity is comparable for chronic users. The slower offset means symptoms emerge over days rather than hours, but the cumulative withdrawal burden is similar. Seizure risk applies the same as with other benzodiazepines.

Lamictal (lamotrigine) does not produce a classical withdrawal syndrome. The clinically important risks are: (1) seizure recurrence in patients taking lamotrigine for epilepsy, and (2) return of bipolar depression in patients taking it for mood stabilization. Abrupt cessation should be avoided in both populations.

Latuda (lurasidone) has a moderate discontinuation profile. As with other antipsychotics, the clinically important concerns are return of underlying psychiatric symptoms and rare withdrawal dyskinesia.

Lexapro (escitalopram) has a moderate discontinuation profile - generally better-tolerated than Paxil or Effexor, but real symptoms still occur, especially after long-term use or rapid taper. Most patients can taper Lexapro without significant difficulty when the schedule is slow enough.

Librium (chlordiazepoxide) has a withdrawal pattern similar to Valium given the long half-life and active metabolites. Less commonly used now for chronic anxiety; main current use is in alcohol withdrawal protocols. Same seizure risk applies for chronic users who stop abruptly.

Lithium has a unique discontinuation profile distinct from antidepressant or benzodiazepine withdrawal. The pharmacology doesn't produce a classical "withdrawal syndrome." The clinically important phenomenon is the risk of mania or rapid-cycling on discontinuation, particularly with abrupt cessation. Patients with bipolar disorder who stop lithium are at substantially elevated risk of relapse, sometimes more severe than their pre-treatment episodes.

Lunesta (eszopiclone) has a slightly longer half-life than Ambien and a somewhat smoother discontinuation profile, but the same fundamental rebound-insomnia pattern applies. Chronic use produces dependence and stopping reliably produces rebound effects.

Luvox sits between the easy SSRIs (Prozac, Lexapro) and the difficult ones (Paxil) for discontinuation. The shorter half-life means symptoms emerge faster and feel more intense than with longer-acting SSRIs. Less commonly prescribed than Zoloft or Lexapro, so patient communities discussing withdrawal are smaller, but the pattern is real.

Marplan (isocarboxazid) has a discontinuation pattern similar to Nardil. Less commonly prescribed than Nardil or Parnate, and the same general MAOI considerations apply.

Nardil (phenelzine) has a discontinuation pattern that is pharmacologically benign compared to SSRIs, but the dietary restrictions ending and the gradual return of normal MAO function over 2 weeks produces its own pattern. Patients tapering MAOIs often describe sleep changes and the return of depression as the dominant experiences.

Nortriptyline (Pamelor) has a similar discontinuation pattern to amitriptyline but tends to be milder overall, in part because it has less anticholinergic activity. The cholinergic rebound syndrome is less pronounced. Most patients taper without significant difficulty.

Parnate (tranylcypromine) has a discontinuation pattern similar to Nardil but with more amphetamine-like properties (tranylcypromine has structural similarity to amphetamines). Some patients describe a stimulant-like crash when stopping in addition to the gradual MAO normalization.

Paxil (paroxetine) is widely recognized as the SSRI with the most severe discontinuation syndrome, comparable to Effexor in difficulty. The short half-life, lack of an active metabolite, and significant anticholinergic activity combine to produce vivid withdrawal symptoms within a day of dose reduction. Many patients describe Paxil withdrawal as among the most physically uncomfortable medication-discontinuation experiences in psychiatry.

Pristiq (desvenlafaxine) has a discontinuation profile similar to Effexor, of which it is the active metabolite. Most patients describe Pristiq withdrawal as slightly more manageable than Effexor, but the same short-half-life pattern applies and abrupt cessation produces a real withdrawal syndrome.

Prozac has the mildest discontinuation profile of the SSRIs because its active metabolite norfluoxetine essentially auto-tapers the patient over weeks after the last dose. Some patients can stop Prozac abruptly with no noticeable symptoms at all. This same property is why Prozac is sometimes used as a bridge for patients struggling to taper off short-half-life SSRIs or SNRIs.

Remeron (mirtazapine) has a moderate discontinuation profile. The most distinctive aspect is rebound insomnia and increased anxiety, particularly in patients who were taking Remeron primarily for sleep. The relatively long half-life smooths the washout.

Restoril (temazepam) is typically used at low doses for sleep rather than chronic anxiety, which makes the withdrawal pattern usually milder than Xanax or Ativan. Chronic use at higher doses produces a benzo-pattern withdrawal with the same seizure risk on abrupt cessation.

Rexulti (brexpiprazole) has a mild discontinuation profile similar to Abilify, helped by its very long half-life. Return of underlying symptoms is the most clinically important concern.

Risperdal (risperidone) has a moderate discontinuation profile. The relatively short half-life of the parent drug and shorter overall washout means rebound effects can emerge more quickly than with longer-acting agents like Abilify or Vraylar.

Ritalin (methylphenidate IR) has a discontinuation pattern similar to amphetamines but tends to be milder because methylphenidate produces less peripheral catecholamine release than amphetamines. The crash is real but usually shorter in duration than Adderall. The short half-life means inter-dose dips are common even during regular use, so the body is somewhat adapted to the rise-and-fall pattern.

Savella (milnacipran) has a pronounced discontinuation pattern driven by its very short half-life. In the US it is FDA-approved for fibromyalgia rather than depression. Patients tapering Savella often experience a return of both fibromyalgia symptoms and the discontinuation syndrome itself, which can be hard to separate.

Seroquel (quetiapine) has a notable discontinuation pattern dominated by rebound insomnia and anxiety, particularly in patients using it primarily for sleep. The relatively short half-life makes rebound effects emerge quickly. For psychiatric indications, relapse risk is the more clinically important concern.

Sonata (zaleplon) has the shortest half-life of the Z-drugs, which makes it less likely to produce next-day residual effects but more likely to produce middle-of-night awakening. Discontinuation is generally mild because chronic dependence is less common with such a short-acting agent.

Tegretol does not produce a classical withdrawal syndrome. The discontinuation considerations are similar to Depakote: bipolar relapse risk and seizure recurrence risk warrant slow tapering. Tegretol's auto-induction of its own metabolism (and many other drug metabolisms) makes drug-interaction considerations during tapering important.

Trazodone has a mild discontinuation profile. Most outpatient use is at low doses (50-200 mg) for sleep rather than antidepressant doses (300-600 mg), and low-dose discontinuation is typically uneventful. Higher doses used for depression can produce a more notable withdrawal pattern.

Trileptal does not produce a classical withdrawal syndrome. The same considerations as other mood stabilizers / anticonvulsants apply: bipolar relapse risk and seizure recurrence risk warrant slow tapering. Generally has fewer drug interactions than Tegretol.

Trintellix (vortioxetine) has a relatively mild discontinuation profile, helped substantially by its long half-life. Compared to SSRIs and especially SNRIs, withdrawal symptoms are less intense and less common. The FDA labeling does not require a tapering schedule for most patients, although a gradual reduction is still good practice.

Valium (diazepam) has the most gradual withdrawal pattern of the commonly-prescribed benzodiazepines because of its very long half-life and multiple active metabolites. This is why diazepam is the standard bridge medication in the Ashton method for tapering shorter-acting benzodiazepines. Seizure risk with abrupt cessation still applies for chronic users.

Viibryd has a moderate discontinuation profile similar to other SSRIs with comparable half-lives. The 5-HT1A partial agonist activity does not appear to substantially alter the withdrawal pattern compared to pure SSRIs.

Vraylar (cariprazine) has the most gradual discontinuation profile of any antipsychotic because its active metabolite has an extraordinarily long half-life (1-3 weeks). Withdrawal effects emerge over weeks rather than days.

Vyvanse has a discontinuation pattern similar to Adderall but typically smoother because the prodrug conversion produces a more gradual serum-level curve (no peaks and troughs the way IR amphetamine does). Patients report less pronounced "crash" feeling on stopping Vyvanse compared to Adderall IR, but the underlying rebound physiology is the same.

Wellbutrin (bupropion) has a notably mild discontinuation profile compared to SSRIs and SNRIs. Because it works on dopamine and norepinephrine rather than serotonin, it does not produce the classic SSRI discontinuation syndrome (brain zaps, dizziness, GI distress). Most patients can taper Wellbutrin with little difficulty.

Xanax (alprazolam) has one of the most severe withdrawal syndromes of any benzodiazepine, comparable to short-acting alcohol withdrawal. Abrupt cessation after chronic use can produce seizures, which is a medical emergency. The combination of high potency, short half-life, and rapid onset of action makes Xanax both the most popular and the most physically dependence-forming benzo. Tapering MUST be done under medical supervision.

Zoloft has a moderate discontinuation profile, generally better tolerated than Paxil or Effexor but more pronounced than Prozac. Most patients can taper without significant difficulty when the schedule is gradual. Symptoms tend to be flu-like rather than the dramatic brain-zap-and-vertigo pattern seen with short-half-life agents.

Zyprexa (olanzapine) has a moderate discontinuation profile. Rebound insomnia and anxiety are common in the first 1-2 weeks. Return of underlying psychiatric symptoms is the more clinically important long-term concern. Withdrawal dyskinesia, while uncommon, is recognized.